A high-affinity FLNaABD mutant reveals the actin-binding interface at near-atomic resolution. To understand FLNaABD binding to F-actin and potentially explain the molecular basis of disease mutations, we used cryo-EM to visualize the complex between F-actin and an FLNaABD construct encompassing the N-terminal 42 residues plus the tandem calponin homology domains. In initial experiments with wild-type (WT) FLNaABD and phalloidin-stabilized F-actin on an FEI F20 Tecnai electron microscope, we were only able to reproduce low-resolution structures similar to those seen in other ABDActin-cross-linking proteins assemble actin filaments into higher-order structures essential for orchestrating cell shape, adhesion, and motility. Missense mutations in the tandem calponin homology domains of their actin-binding domains (ABDs) underlie numerous genetic diseases, but a molecular understanding of these pathologies is hampered by the lack of highresolution structures of any actin-cross-linking protein bound to F-actin. Here, taking advantage of a high-affinity, diseaseassociated mutant of the human filamin A (FLNa) ABD, we combine cryo-electron microscopy and functional studies to reveal at near-atomic resolution how the first calponin homology domain (CH1) and residues immediately N-terminal to it engage actin. We further show that reorientation of CH2 relative to CH1 is required to avoid clashes with actin and to expose F-actinbinding residues on CH1. Our data explain localization of disease-associated loss-of-function mutations to FLNaCH1 and gain-of-function mutations to the regulatory FLNaCH2. Sequence conservation argues that this provides a general model for ABD-F-actin binding.
A ctin cross-linking proteins mediate assembly of actin filaments into higher-order structures, such as bundles and orthogonal networks, that play essential roles in determining cell morphology and behavior 1, 2 . Defects in the actin cytoskeleton underlie numerous genetic diseases, and can arise from missense mutations in the ABDs of these cross-linking proteins [3] [4] [5] . Crystal structures of isolated ABDs have shown that they are composed of tandem calponin homology domains 4-7 but a complete molecular understanding of actin binding or its perturbation in disease has been hampered by the lack of a high-resolution structure of any actin-cross-linking protein bound to F-actin.
Before publication of the first ABD crystal structures, three ABD actin-binding sites (ABSs; ABS1, ABS2, and ABS3) were predicted based on peptide and fragment binding studies and mutagenesis of a variety of ABDs [8] [9] [10] [11] [12] [13] . However, their precise boundaries and relative contributions to F-actin binding were controversial and ABD crystal structures subsequently revealed that the three putative ABSs do not form a continuous surface and include many buried residues 4, 7, 14 . Indeed, ABS1, which lies in the first helix of CH1, is largely buried at the interface between CH1 and CH2 in the 'closed' conformation of the ABD observed in most crystal structures [14] [15] [16] . This, together with biophysical experiments and electron microscopy studies of ABDs bound to F-actin [17] [18] [19] [20] [21] [22] , led to models where inter-domain rearrangement opens the tandem calponin homology domains, exposing CH1 domain ABSs and removing steric clashes between CH2 and actin that would prevent binding. The conformational equilibrium between 'closed' and 'open' states would thus determine ABD binding to F-actin, but the identity of the actin-binding residues and the nature of the conformational changes remained to be determined.
The essential actin-cross-linking protein FLNa is composed of an N-terminal ABD followed by 24 immunoglobulin-like domains, the last of which mediates homodimerization 23 . In addition to crosslinking F-actin, FLNa binds numerous scaffolding, signaling, and transmembrane proteins, and so plays vital roles in the regulation of cell morphology, adhesion, migration, differentiation, and mechanical force sensing 24, 25 . Consistent with these essential roles, non-sense or frameshift mutations in the gene for FLNa, which is on the X chromosome, are typically embryonically lethal in males 3, 26 . In heterozygous females, null FLNa mutations cause periventricular nodular heterotopia (PVNH), a neuronal differentiation or migration disorder often also associated with cardiovascular abnormalities 27, 28 . Notably, PVNH can also be caused by rare missense mutations that cluster in the FLNaCH1 domain, suggesting that these point mutations result in a loss of function, possibly by disrupting F-actin binding, but this has not been experimentally tested 27, 29 . In contrast, missense point mutations in the FLNaCH2 domain are linked to developmental malformations associated with otopalatodigital syndrome spectrum disorders (OPDSDs). Unlike PVNH mutations, OPDSD mutations are believed to confer a gainof-function effect on FLNa 7, 30, 31 , and in the case of the E254K mutation increased affinity for F-actin has been reported 7 . Here, we employed cryo-electron microscopy (cryo-EM) and biochemical and cellular assays to investigate and characterize the mechanism of ABD binding to F-actin and to rationalize FLNa human disease mutations in molecular detail. Fig. 1a,b ). In an attempt to improve ABD decoration of actin filaments and increase resolution, we performed experiments using FLNaABDs containing OPDSD-associated gain-of-function point mutations in FLNaCH2 7 . This yielded 6.6-Å and 7.4-Å resolution maps for the Q170P and E254K mutants, respectively (Table 1 and Supplementary Fig. 1a,c,d) . Notably, the FLNaABD-E254K map included density for the CH2 domain, albeit at lower resolution ( Supplementary Fig. 1d ). We therefore used a Titan Krios electron microscope to image FLNaABD-E254K in complex with F-actin, allowing us to approach atomic resolution, resolving both the CH1 domain and F-actin to 3.6-Å resolution ( Fig. 1a and Supplementary  Fig. 1a ). The CH2 domain was also visible, but again was at lower resolution, and is described further in later sections. The F-actin structure in the complex is indistinguishable from previously reported structures of phalloidin-stabilized F-actin (Protein Data Bank (PDB) 6C1D, root mean squared deviation of Cα atoms in residues T5-C374 is 0.713 Å) 32 .
Until now, mapping ABSs in ABDs has been contentious; three putative sites (ABS1, -2, and -3) have been proposed, but there has been a lack of consensus on the boundaries of these sites and crystallographic data have been unable to reconcile these sites with a continuous binding surface 4, 7 . Contrary to prior predictions, our structure reveals that neither the proposed ABS1 (coarsely mapped to residues 46-56) in helix-A of CH1 nor ABS3 (residues 163-181) in helix-A of the CH2 domain directly engages F-actin. Instead, the ABD binds F-actin through a short sequence immediately N-terminal to the CH1 domain (residues L35-K42), which we term ABS-N, as well as the predicted ABS2 (residues V122-W142) and structurally adjacent residues R91-L104, which were not previously implicated in F-actin binding and which we term ABS2' (Fig. 1b) . These sites mediate ABD binding in the groove between subdomains 1 and 2 on one actin monomer (n) (1,348 Å 2 of buried surface area) and subdomain 1 on the adjacent (n + 2) monomer (burying 505 Å 2 ) ( Fig. 1b ).
FLNa residues immediately N-terminal to CH1 contribute to F-actin binding. Although most of the actin-bound FLNaCH1 domain in our cryo-EM structure closely resembles that of the unbound FLNaABD-E254K crystal structure (PDB 3HOC, root mean squared deviation of Cα atoms in residues A39-S149 is 1.094 Å), the first turn of helix-A rearranges to engage F-actin, and we can resolve additional N-terminal residues 29-38 that were largely disordered in prior FLNa X-ray structures 6, 7 (Fig. 2a,b ). To test the importance of this region in F-actin binding, we generated a series of N-terminal truncations of C-terminally green fluorescent protein (GFP)-tagged FLNaABD constructs (FLNaABD-GFP) and assessed co-localization with F-actin in transfected NIH-3T3 fibroblasts. Briefly, GFP targeting to actin stress fibers was assessed in each GFP-positive cell by a sample-blind observer using an actintargeting score ranging from 1 (no targeting) to 7 (strong targeting); additionally, overall co-localization of GFP and F-actin signals within cells was assessed by calculation of Pearson's correlation coefficient (PCC) (see Methods). Both methods indicated that, whereas loss of amino acids 1-27 or 1-32 had no impact on F-actin co-localization, loss of 1-37 or 1-40 partially inhibited co-localization and loss of 1-44 abrogated it (Fig. 2c,d and Supplementary  Fig. 2a ,b)-implicating residues 33-44, encompassing ABS-N, in F-actin binding. Immunoblotting of cell lysates confirmed that all FLNaABD-GFP constructs were expressed at their expected molecular weights ( Supplementary Fig. 2b ). Of these N-terminal residues, only 37-44 are visible in FLNaABD X-ray crystal structures 6, 7 , forming the N terminus of the first α helix (helix-A). In the actin-bound conformation, the N terminus of helix-A is deformed, moving up to ~3 Å ( Fig. 2b) to engage actin via a probable cation-π interaction between W41 (conserved in the ABD of all filamins and α -actinins, Supplementary Note) and actin R28, potentially buttressed by additional interactions with actin F21 and R95 ( Fig. 2e ,f). Mutating W41 inhibited FLNaABD targeting to F-actin in cells (Fig. 2g,h and Supplementary Fig. 2c,d) , further supporting the importance of this region in actin binding. Moreover, we previously reported that a double K42R,K43R mutation in FLNa helix-A inhibits actin binding 33 and our structure shows that K42 may help stabilize ABS-N ( Fig. 2f ). Residues N-terminal to helix-A also contribute to actin binding, and the importance of hydrophobic contacts between L35 and actin as seen in our structure is supported by the strongly impaired F-actin targeting of an L35A mutant (Fig. 2g,h and Supplementary Fig. 2c,d ). Together, our structural and functional studies firmly establish the biological relevance of ABS-N in ABD-actin binding. Furthermore, despite low sequence conservation of this region, recent biochemical studies on utrophin 34 and a lower-resolution cryo-EM structure of the actin-bound β -IIIspectrin ABD 22 indicate a general role of the ABD N terminus in actin binding.
ABS2' and ABS2 facilitate binding in the groove between adjacent actin subunits. Beyond the ABS-N site, the remaining ABD interface with actin is mediated by ABS2 and ABS2' . ABS2' extends from the middle of the C-E loop into the N terminus of helix-E and engages both subdomain 2 of the primary interacting actin subunit(n) and subdomain 1 of the adjacent actin(n + 2)-mainly via hydrophobic and H-bonded interactions (Fig. 3a) . We validated the importance of these interactions by mutating R91, which is well positioned to form an H-bond with T351 in actin(n + 2); F99, which contacts I345 in actin (n + 2); and L104, which is stabilized by CH1-V130 to make a hydrophobic contact with M47 in actin(n). R91E, F99A, and L104A mutations each inhibited binding in the cellular F-actin-targeting assay (Fig. 3b ,c and Supplementary Fig. 3a ). ABS2 encompasses part of the E-F loop, the short helix-F and the N-terminal half of helix-G, and engages actin(n) subdomains 1 and 2 ( Fig. 3d ). We previously reported that a K135R substitution in ABS2 strongly inhibits actin binding 33 and now show that the K135A mutation has a similar effect ( Fig. 3e ,f and Supplementary  Fig. 3b ). K135 is highly conserved across all ABDs (Supplementary Note) and its sidechain density is directly resolved, indicating potential ionic interactions with actin E93 and D56 (Fig. 3d ). The importance of ABS2 is further supported by the strong inhibition of F-actin targeting of a charge-reversing lysine mutation at D125, which forms an ionic bond with K61 and potentially H-bonds with Y53 on actin ( Fig. 3d-f and Supplementary Fig. 3b ).
FLNaABD-E254K binds F-actin in an open conformation.
Further examination of our structure reveals the necessity for substantial CH2 domain reorientation to prevent steric clashes with F-actin on ABD binding. In our WT and OPDSD mutant Q170P structures ( Supplementary Fig. 1a -c), as well as other published lower-resolution structures 18, 19, 22 , density for the CH2 domain was not evident, consistent with CH2 domain motion in the F-actinbound form. In contrast, in both our F20 and Krios E254K structures the CH2 domain is apparent, albeit with weaker cryo-EM density and at lower resolution than the rest of the map ( Fig. 4a and Supplementary Fig. 1d ). The lower resolution of this domain again indicates its mobility but was sufficient to reveal that it is oriented outwards and away from actin. Comparison of our actin-bound FLNaABD-E254K structure with the closed conformation seen in the FLNaABD-E254K crystal structure 7 indicates that the closed conformation is incompatible with F-actin binding. As reported previously for α -actinin 19 , superposition of the CH1 domains in the actin-bound crystal structures reveals that, in the closed conformation, CH2 would clash with F-actin ( Fig. 4b ). We therefore conclude that an outward movement of the CH2 domain facilitates CH1-mediated binding to actin ( Fig. 4c ). Consistent with this model, isolated FLNaCH1-GFP strongly targeted to F-actin 33 while FLNaCH2-GFP showed no targeting, even with OPDSD mutations Q170P or E254K which otherwise promoted ABD targeting ( Fig. 4d ,e and Supplementary Fig. 4a,b ).
In addition to avoiding steric clashes with actin, our structure reveals that CH2 reorientation also exposes a previously unrecognized and highly conserved actin-binding residue (W142) at the C terminus of ABS2. Notably, in unbound FLNaABD crystal structures W142 interacts with H255 in CH2, possibly 'latching' the ABD in a closed conformation ( Fig. 5a ). In contrast, in our actin-bound structure, this interaction is replaced by hydrophobic contacts between W142 and actin ( Fig. 5b) , and a W142A mutation inhibited targeting to F-actin in cells ( Fig. 5c,d and Supplementary Fig.  4c ). These data argue that W142 plays a regulatory role by binding either CH2 in a closed inhibitory state, or F-actin in the open active a, The cryo-EM map (left and middle) has been filtered to 3.6-Å resolution, masked to illustrate the actin and FLNaCH1 region, and fit with computationally refined models (right) for actin (different subunits in dark blue, cyan, and light blue) and the FLNaCH1 domain (green). Phalloidin (orange) and Mg.ADP (grey) were resolved within F-actin. b, The binding interface of the FLNaABD (green ribbon) consists of the N-terminal ABS (ABS-N, pink), ABS2 (yellow), and the ABS2 extension (ABS2', red), which makes contacts with actin subunits (n) (dark blue, surface representation) and (n + 2) (light blue, surface representation) on actin subdomains 1 and 2 (SD1 and SD2, labeled in grey).
conformation. In α -actinin-4, the homologous W147 may serve a similar role by engaging K255 in CH2. Consistent with this, K255 mutations that presumably unlatch the ABD and increase affinity for F-actin are associated with the kidney disease focal segmental glomerulosclerosis 35 . Indeed, disease-associated gain-of-function mutations are found throughout the CH2 domain of FLNa and other ABDs including in its hydrophobic core (Supplementary Note). Purified OPDSD-associated mutant FLNaABDs (Q170P or E254K) analyzed by scanning fluorimetry exhibited sharp melting points at lower temperatures than WT FLNaABD, indicative of altered stability ( Fig. 5e ). Consistent with their enhanced F-actin targeting (Fig. 4d ,e and Supplementary Fig. 4a,b ), OPDSD-associated ABD mutants also displayed increased affinity for F-actin in co-sedimentation assays (Fig. 5f ,g and Supplementary Fig. 4d ). We hypothesize that OPDSD mutations destabilize the CH2 domain in the closed ABD position and shift the conformational equilibrium in favor of ABD opening, facilitating CH1-mediated F-actin binding.
FLNa CH1 domain disease mutations confer loss of function.
In addition to the gain-of-function CH2 domain mutations that cause OPDSD, mutations in FLNa are also linked to the neuronal migration disorder PVNH 27 . Most FLNa PVNH mutations are non-sense and frameshift, resulting in the loss of FLNa protein 3, 27 . However, rare PVNH-associated missense mutations that cluster in the FLNaCH1 domain are also seen, and result in phenotypically similar, albeit somewhat milder, disease 27 . We propose that these mutations, many of which are found in the ABS-N, ABS2, and ABS2' (Supplementary Note), disrupt the actin-binding interface and cause a loss of function. Consistent with this, the PVNH mutations A39G and A128V strongly impaired FLNaABD targeting to F-actin in cells (Fig. 6a,b and Supplementary Fig. 5a ) and F-actin binding in in vitro co-sedimentation assays (Fig. 6c,d and Supplementary  Fig. 4d ). Our ability to purify soluble recombinant FLNaABD mutants with size-exclusion chromatography (SEC) profiles consistent with monomeric protein ( Supplementary Fig. 5b ) argues that the mutations do not result in general misfolding. This conclusion is supported by their sharp melting points in differential scanning fluorimetry experiments ( Fig. 6e) . Notably, despite a WT melting point and elution profile ( Fig. 6e and Supplementary Fig. 5b ), indicating that FLNaABD A39G is properly folded, it does not appear to bind actin with the 1/1 ratio seen for the WT and other gain-and loss-of-function mutations ( Fig. 6c and Supplementary Fig. 4d ). This suggests an anomalous binding mechanism. We propose that A39 (in ABS-N) normally stabilizes the actin-binding residue W41 ( Fig. 2e,f ). While loss of this stabilization is likely to account for the observed reduction in binding affinity, it is difficult to envisage how it also alters stoichiometry of binding, either by occluding adjacent binding sites or by altering F-actin conformation. As this low-occupancy, low-affinity interaction is not conducive to structural analysis, we cannot currently explain the reduced stoichiometry of FLNaABD A39G. For a second PVNH mutation, A128V, we note that A128 does not make direct contact with F-actin but packs tightly behind the main interacting surface of ABS2 (helix-F). An A128V substitution would perturb this surface ( Supplementary Fig. 5c ), probably explaining its disruption of actin binding and possibly contributing to the decrease in thermal stability seen in scanning fluorimetry experiments ( Fig. 6e ). Our structure also allows us to rationalize the previously unexplained M102V PVNH-associated mutation that lies in ABS2' and inhibited F-actin binding in cells (Fig. 6a,b and Supplementary Fig. 5a ). M102, in conjunction with F99, extends towards I345 of actin(n + 2) ( Fig. 3a ) and substitution with the shorter valine probably prevents this interaction. Two other PVNH-associated FLNa mutations that lie outside the actin-binding interface (E82V and S149F) had little or no effect on F-actin targeting, producing only modestly reduced actin-targeting scores but no reduction in PCC (Fig. 6a,b and Supplementary Fig.  5a,d) ; the basis for their clinical effects remains unclear. Additional FLNaCH1 domain PVNH mutations also occur in ABS2. The V122 side chain is wedged between H87 and H88 of actin(n) and a V122G mutation strongly inhibited association with F-actin ( Fig. 6a,b and Supplementary Fig. 5a ). The K127N severely inhibited actin targeting, and in our structure K127 is in range to make an ionic bond with E167 in actin(n + 2) (Fig. 6a,b and Supplementary Fig 5a) .
Notably, disease-associated mutations in the ABD of FLNc and α -actinin-2 also localize to regions corresponding to FLNa ABS2 36, 37 (Supplementary Note). Mutations at I119 inhibited F-actin binding (Fig. 6a,b and Supplementary Fig. 5a ), probably due to disruption of the hydrophobic core of CH1, and α -actinin-1 and -2 also contain disease-associated mutations in this region 38, 39 .
Discussion
Our high-resolution cryo-EM structure of FLNaABD-E254K bound to F-actin provides a detailed foundation for understanding the molecular basis of actin binding by tandem calponin homology domains, revealing several new features of the ABD-actin binding mechanism. We show that, on actin binding, FLNa residues immediately N-terminal to the CH1 domain become ordered and contribute to F-actin binding. By identifying three ABSs (ABS-N, ABS2' , and ABS2), we resolve controversy surrounding the specific sites involved in F-actin binding. We find that ABS-N participates in hydrophobic and potential cation-π interactions with subdomain 1 of actin, while ABS2' binds an adjacent F-actin subunit.
The previously mapped ABS2 also makes key ionic and hydrophobic interactions. The functional importance of each of these sites was validated using structure-guided mutations. Our structure also indicates CH2 domain movement associated with actin binding, establishing that, as previously proposed based on earlier lowerresolution structures 18, 19, 22 , binding involves ABD opening and does not involve direct CH2-actin interactions. In addition to avoiding steric clashes of the CH2 domain with actin, ABD opening exposes the highly conserved actin-binding residue W142 in ABS2 which, in the closed conformation, binds the CH2 domain, serving as a regulatory latch to stabilize the closed ABD. Finally, combining cellular and biochemical analysis of disease-associated FLNaABD mutations with our structural studies helps explain the localization of PVNH disease-associated loss-of-function point mutations to the actin-binding CH1 domain and gain-of-function OPDSD mutations to the regulatory CH2 domain. The N-terminal flanking regions of ABDs are diverse in length and sequence, but the ABS-N sequence is conserved in filamins and α -actinins (Supplementary Note) and, despite relatively low sequence similarity with the FLNa N terminus, deletion of residues 1-27 in utrophin ABD or 1-51 in β -III-spectrin ABD has been shown to dramatically reduce F-actin binding 22, 34 . Thus, residues N-terminal to CH1 have functionally conserved biological significance in multiple ABDs.
Notably, at least in the case of FLNa, residues preceding ABS-N are not necessary for actin binding as N-terminal truncations (Δ 1-27 and Δ 1-32) did not diminish ABD co-localization with F-actin. Consistent with this, an alternative FLNa transcript that results in initiation at M28 (equivalent to our Δ 1-27 ABD) produces functional FLNa protein that targets to F-actin 40 . Furthermore, FLNb also has a relatively short N terminus (equivalent to the Δ 1-27 FLNaABD) and the FLNbABD binds F-actin with affinities comparable to the FLNaABD in the present study 41 . This suggests that the variability in sequence N-terminal to ABS-N may provide mechanisms to regulate ABD binding to actin. Indeed, calmodulin binding to N-terminal residues of plectin has been proposed to regulate plectin interactions with F-actin 42, 43 . Calmodulin has also been reported to inhibit FLNa binding to F-actin 44 but, rather than binding the N-terminal region, calmodulin was proposed to utilize a cryptic binding site (residues 87-96) in the FLNaCH1 domain that became exposed upon F-actin binding. We now show that the proposed calmodulin-binding site faces away from F-actin and we observe no substantial conformational changes in this site upon F-actin binding, making it unclear how calmodulin would selectively bind this region in the FLNaABD-F-actin complex to drive dissociation. Furthermore, despite the strong sequence and structural conservation between FLNa and FLNb, calmodulin did not inhibit FLNb binding to F-actin 41 . The structural basis for any effect of calmodulin on FLNa binding to F-actin therefore remains to be determined.
FLNa binding to F-actin is, however, clearly influenced by the CH2 domain and our structural data show that, when bound to F-actin, the FLNaABD domain adopts an 'open' position distinct from the closed conformations seen in FLNaABD crystal structures 6, 7 . However, even in the F-actin-bound FLNaABD E254K structure, the lower resolution of the CH2 domain reveals that this domain is mobile and this presumably explains why it was not visible in most other ABD-actin complexes 19, 22 . An open conformation is necessary to avoid steric clashes with actin and to expose the otherwise occupied F-actin binding residue W142 in ABS2. Right, assay data points were plotted to generate a binding curve to calculate an apparent dissociation constant (K d ). g, Apparent K d was averaged for each ABD from at least six co-sedimentation assays. Bars = mean ± s.e.m., n = number of independent co-sedimentation assays, *significantly different from WT in an unpaired two-tailed t-test (WT versus Q170P, t = 2.501, df = 14, P = 0.0254; WT versus E254K, t = 4.086, df = 14, P = 0.0011) (see also Supplementary Fig. 4d ). Source data for panels c, d, and g are available online. dF/dT, XXX; Sup, supernatant.
Notably, W142 plays alternative functional roles by either binding F-actin when the ABD is in an open conformation or binding CH2 in the closed unbound conformation. W142 is completely conserved across ABDs (Supplementary Note) and has been implicated in latching α -actinin-4 35 and plectin 45 closed, indicating that this switching mechanism may be conserved mechanism for controlling the conformational equilibrium of many, if not all, tandem calponin homology ABDs. Our cellular and biochemical studies demonstrate loss of actin binding with most of the human PVNH mutations that localize to FLNaCH1. While some appear to disrupt direct molecular interactions with F-actin (M102V, V122G, K127N), others probably elicit their effects by deforming ABSs or the CH1 domain in general (A39G, I119D, A128V). Conversely, we propose that the FLNaABD exists in a conformational equilibrium in solution and that the gain-of-function OPDSD mutations in the CH2 domain exert their effects by shifting that equilibrium towards open states. The decreased melting temperature and increased affinity of FLNaABD-E254K and -Q170P for F-actin (this report and ref. 7 ) are consistent with this model but solution dynamics experiments, Bars = mean ± s.e.m., n = number of scored cells from at least three independent experiments, *significantly different from WT (P < 0.001) in a one-way ANOVA (F 9,1680 = 227.5) with Dunnett's multiple comparisons test. b, PCC scoring of PVNH disease mutant FLNaABD-GFP. Center = median, boxes = 25th-50th and 50th-75th percentiles, whiskers extend to 10th and 90th percentiles, n = number of scored cells from at least three independent experiments, *significantly different from WT (P < 0.001) in a one-way ANOVA (F 9,1234 = 27.64) with Dunnett's multiple comparisons test. c, Left, representative Coomassie-stained actin co-sedimentation assay gels containing pellet (top) or supernatant (bottom) samples with no-actin controls (middle) for purified WT, A39G, and A128V FLNaABDs. Uncropped gel images are shown in Supplementary Data Set 1. Right, assay data points were plotted to generate a binding curve to calculate an apparent dissociation constant (K d ). d, Apparent K d was averaged for FLNaABD-WT, -A39G, or -A128V protein from at least four assays (WT here is the same as appears in Fig. 5g for comparison purposes) . Bars = mean ± s.e.m., n = number of independent co-sedimentation assays, *significantly different from WT in an unpaired two-tailed t-test (WT versus A39G, t = 4.163, df = 13, P = 0.0011; WT versus A128V, t = 5.934, df = 12, P < 0.0001) (see also Supplementary Fig. 4d ). e, Triplicate derivative melting curves from differential scanning fluorimetry for purified WT, A39G, and A128V FLNaABDs indicate a single melting temperature peak for each protein (WT here is the same as appears in Fig. 5e as recently applied to the β -III-spectrin ABD 22 , will be required to test it further. Notably, the FLNaABD is apparently also dynamic even when bound to F-actin, and this motility presumably accounts for the lower resolution (or lack of resolution) of the CH2 domain in actin-bound structures 19, 22 , and suggests that there may be many 'open' conformations compatible with actin binding.
In conclusion, our work provides structural and functional insight into the ramifications of FLNa disease mutations and resolves substantial controversies in mapping the ABSs of tandem calponin homology domains.
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Methods
Reagents and DNA constructs. Polyclonal anti-GFP (600-101-215, Rockland), anti-vinculin (V9131, Sigma-Aldrich), secondary anti-goat-680RD (926-68074, LI-COR), secondary anti-mouse 800CW (925-32212, LI-COR), and Alexafluor-568-phalloidin (Life Technologies) were purchased. Polyclonal anti-human FLNa antibody, which cross-reacts with mouse FLNa, was raised in rabbits 46, 47 . Fibronectin solution (1 mg ml −1 ) was purchased (F1141, Sigma). Human FLNa-ABD and -CH domain constructs in a pcDNA3 vector with a C-terminal GFP tag have been described previously 33, 48, 49 . FLNa mutations were generated by QuikChange site-directed mutagenesis (Stratagene). For bacterial expression, select FLNa-ABD constructs were also subcloned into a modified pET32-6xHis vector using KpnI and EcoRI restriction sites to generate N-terminally His-tagged FLNaABD.
Cell culture. Mouse NIH3T3 cells were obtained from Yale colleagues and tested negative for mycoplasma contamination. Cells were cultured in DMEM (11965, GIBCO) with 9% bovine serum (16170078, GIBCO) and penicillin/streptomycin (15140122, GIBCO), and incubated at 37 °C in a humidified atmosphere containing 5% CO 2 . To express FLNa constructs, 8 × 10 4 cells per well were plated in a 6-well dish and 24 h later were transfected with 1.5 µ g plasmid DNA using polyethyleneimine (23966-1, Polysciences Inc.).
Actin filament targeting and microscopy. Transfected cells were plated on coverslips previously coated with 5 µ g ml −1 fibronectin and cultured for 24 h. Cells were washed with PBS and then fixed and permeabilized in cold 4% paraformaldehyde + 0.1% Triton X-100 in cytoskeletal buffer (10 mM MES, pH 6.1, 150 mM NaCl, 5 mM EGTA, 5 mM MgCl 2 , 5 mM glucose) for 30 min at room temperature. Coverslips were washed with PBS and incubated in cytoskeletal buffer containing 0.2% BSA, 50 mM NH 4 Cl, and 0.3% Triton X-100 for 1 h at room temperature, then incubated for 1 h at room temperature with Alexafluor-568-Phalloidin in the same buffer and washed in PBS. Coverslips were mounted onto glass slides using ProLong Diamond Antifade Mountant (P36965, Invitrogen). Microscopy images of transfected cells expressing comparable levels of GFP were acquired using a Nikon Eclipse Ti microscope with a × 100 objective using Micro-Manager software 50 and analyzed in ImageJ (National Institutes of Health, rsb. info.nih.gov). To quantify GFP-tagged FLNaABD targeting to actin filaments, co-localization of GFP and phalloidin-568 signal was scored on a scale of 1 (low overlap) to 7 (high overlap) in a sample-blind manner. To avoid potential bias in assigning co-localization scores, GFP and phalloidin-568 signal images were also subjected to an automated CellProfiler co-localization function 51 to normalize images and calculate the PCC between the two images. Images were excluded from automated PCC scoring if the field contained non-expressing or multiple cells. In all cases, the expression of the GFP-tagged FLNa construct at the predicted molecular weight was confirmed by immunoblotting against GFP, while vinculin was used as a loading control.
Protein purification. 6xHis-tagged FLNaABD DNA constructs were expressed in Rosetta strain Escherichia coli and induced with 500 µ M isopropyl-β -dthiogalactoside for 18 h at 16 °C. Bacterial cultures were pelleted and resuspended in lysis buffer (20 mM Tris pH 7.9, 500 mM NaCl, 5 mM imidazole, 1 mM phenylmethyl sulfonyl fluoride, 1% Triton X-100, 700 µ g ml −1 lysozyme, 6.4 µ g ml −1 DNAse1) at 4 °C. 6xHis-tagged proteins were purified over Ni-NTA beads (70666, Novagen), eluted with 400 mM imidazole, and dialyzed into co-sedimentation assay buffer (50 mM Tris pH 8.0, 150 mM KCl, 2 mM MgCl 2 , 0.01% Triton X-100, 5 mM dithiothreitol (DTT)). Proteins were further purified by SEC on a Superdex200 Prep Grade column (GE Healthcare), then concentrated using a 10-kDa MWCO centrifugal filter unit (UFC801024, Millipore), flash frozen in liquid nitrogen, and stored at − 80 °C until use. Purified proteins remained monomeric after concentration and freezing, as seen in SEC (data not shown).
Actin co-sedimentation assays. Actin, purified from chicken breast into G buffer (2 mM Tris pH 8, 200 µ M ATP, 5 mM DTT, 100 µ M CaCl 2 ) and stored at − 80 °C until use, was a gift from the Koleske Lab (Yale) 52 . G-actin (1 µ M) was polymerized with 20 mM imidazole, 150 mM KCl, 2 mM EGTA, 4 mM DTT, and 2 mM MgCl 2 for 30 min at room temperature and stabilized with 1 µ M phalloidin. Polymerized actin was titrated with a range of FLNaABD concentrations in co-sedimentation assay buffer, incubated at room temperature for 1 h, and spun at 270,000g in a Beckman TLA-100 rotor. Supernatants were collected, and protein pellets were washed with co-sedimentation assay buffer then resuspended in water. Then, 30% of the supernatant sample and 100% of the pellet sample were loaded for SDS-PAGE separation. Gels were stained with Coomassie blue, destained, and scanned for densitometry using the Odyssey Infrared Imaging System (LI-COR). No-actin control ABD band intensities were subtracted from the corresponding cosedimented ABD bands to remove F-actin-independent sedimentation signal and divided by the intensity of the actin to normalize for F-actin loading. Data points were fitted to a one-site binding model in Prism software (GraphPad) to calculate apparent binding affinity and stoichiometry 53 .
Differential scanning fluorimetry. His-tagged FLNaABD thermal stability was determined by differential scanning fluorimetry with SYPRO orange 54 (S6650, Invitrogen) using a CFXConnect Real-Time PCR Detection System (BioRad). ABD (30 µ M) in co-sedimentation assay buffer was mixed with SYPRO orange and heated from 4 °C to 95 °C in 1-°C increments over 2 h. Data were collected in triplicate wells using the FAM filter from three independent experiments. Melting temperatures were calculated from the first derivative of the melting curve using the BioRad CFX Manager software.
Cryo-EM sample preparation and data collection.
Purified 6xHis-FLNaABD-WT, -Q170P, or -E254K were incubated at 60 µ M with 15 µ M phalloidin-stabilized F-actin in a low-salt co-sedimentation assay buffer (described above) at least 30 min before freezing. The Q170P and E254K samples were diluted 1/1 in H 2 O immediately before freezing. Samples were prepared using holey carbon grids (Quantifoil R1. Three-dimensional refinement. Micrographs were aligned and dose-corrected using MotionCor2 55 , where subframe motion correction (3 × 3 array) was applied to the WT and Tecnai F20 E254K data sets, while the Krios E254K data set was binned by 2. The Krios E254K data set was corrected for magnification distortion using parameters estimated by mag_distortion_estimate 56 . Contrast transfer function parameters were calculated using Gctf 57 , and micrographs where Gctf did not detect signal at resolutions better than < 4 Å were excluded from structural refinement for the Krios E254K data set. Filaments were manually selected using e2helixboxer from the EMAN software package 58 and extracted at a spacing of ~27.5 Å. The WT, Q170P, and E254K data sets collected on the Tecnai F20 used a box size of 390 pixels, while the Krios E254K data set used a box size of 210 pixels. Structure refinement was performed using iterative helical real space reconstruction single-particle processing 59, 60 as implemented in RELION (version 2.0.3) 61, 62 . The first round of refinement employed masks generated from earlier refinements that were low-pass filtered to 60 Å and included 10-20 Å soft edges using the relion_mask_create tool. The Tecnai F20 E254K and Q170P data sets were further processed in a second round of refinement using a mask generated from the 7 central actin subunits and CH1 domains that were low-pass filtered to 60 Å and included 15 Å soft edges. The Krios E254K data set was also improved in a second round of refinement using a helical mask generated from the results of the first round of refinement but constrained to the central 30% Z-slice, lowpass filtered to 60 Å, and included 6.5 Å soft edges. The WT data were subjected to a particle subtraction and masked three-dimensional classification approach described elsewhere 63 to determine occupancy at the single subunit level. The decorated class (~33% particles) was then restored to its unsubtracted state and further refined using the same mask as earlier in the first round of refinement.
The resolution and B-factor of the final maps were calculated from the Fourier shell correlation (FSC) of independent half-maps in postprocessing with RELION following gold standard protocols ( Supplementary Fig. 1a ). Symmetry was first imposed in real space on the independent half maps in the Tecnai F20 E254K (27.67 Å rise, − 166.89° twist), Q170P (27.52 Å rise, − 166.88˚ twist), and Krios E254K (27.54 Å rise, − 166.73˚ twist) data sets using the relion_helix_toolbox command. The imposed helical parameters were derived from local searches of symmetry on the full map in RELION. The FSC calculations for the Tecnai F20 E254K and Q170P data sets used a mask generated from earlier refinements that was thresholded to contain only actin subunits and CH1 domains, low-pass filtered to 20 Å, and included 15 Å soft edges. The resolution of the Tecnai F20 E254K map reached 7.4 Å, while the Q170P map reached 6.6 Å. The symmetrized Krios E254K volume was used to generate a mask that included only actin and the CH1 domains, was low-pass filtered to 15 Å, and included 8 Å soft edges. This mask was next used in postprocessing calculations, where the final Krios E254K map reached a resolution of 3.6 Å. The final symmetrized Krios E254K map was low-pass filtered to 3.6 Å and sharpened with a B-factor of − 150. The FSC calculations for the WT data set used the same mask from its structural refinement, and reached a resolution of 9.8 Å. The resolution ranges of each map were estimated using blocres from the Bsoft software package 64 .
Model building, refinement, and validation. PDB models of phalloidin-stabilized F-actin (PDB ID 6C1D, chain B, residues 1-375) 32 and FLNa CH1 (PDB ID 3HOC, chain A, residues 39-153) 7 were first fit as rigid bodies into the final symmetrized Krios E254K map using UCSF Chimera 65 . This model was refined against the final map in Phenix 66 using real-space refinement with simulated annealing. Next, the model was refined by manual adjustments and all molecule real-space refinement with Ramachandran restraints in Coot 67 and real-space refinement in Phenix without simulated annealing. After several iterations, additional N-terminal FLNa residues were built by the N-terminal addition of residues into the cryo-EM density in Coot and followed by real-space refinement in Phenix. Multiple subunits and phalloidin subunits (PDB ID 6C1D) were loaded into the neighboring densities and evaluated in MolProbity 68 for steric clashes, which were manually fixed in Coot. Next, structural data for phalloidin (Chemical Entities of Biological Interest identity 8040) 69 was used to generate geometric restraints in eLBOW 70 for realspace refinement with the final map in phenix. The refined phalloidin chains were combined with the model. The final model was evaluated by MolProbity and data statistics are given in Table 1 . Cation-π interactions were investigated using the CaPTURE program 71 . Structural figures were generated in ChimeraX 72 .
Statistics and reproducibility.
For cellular F-actin co-localization experiments, each GFP-tagged FLNa construct or GFP alone was tested in at least 3 independent transfections, with at least 25 image pairs collected for each construct per experiment for quantification. Actin-targeting scores or PCC scores from imaged cells for each construct were averaged and compared to FLNaABD-WT by oneway analysis of variance (ANOVA) (P < 0.0001 for all ANOVAs) with Dunnett's multiple comparisons test; precise values for n, F, and degrees of freedom are listed in the relevant figures and legends. For co-sedimentation assays, each 6xHistagged FLNa protein was tested in at least four independent assays, and average apparent K d of each mutant FLNaABD was compared to WT with an unpaired two-tailed t-test; precise values for n, t, P, and degrees of freedom are listed in the relevant figures and legends. For differential scanning fluorimetry, average melting temperature of each mutant FLNaABD was compared to WT from triplicate wells of three independent experiments by one-way ANOVA (F 4,40 = 339.1, P < 0.0001) with Dunnett's multiple comparisons test.
Reporting Summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.
Data availability
Cryo-EM reconstructions were deposited in the Electron Microscopy Data Bank with the following accession numbers: F20-F-actin-FLNaABD, EMD-7833; F20-F-actin-FLNaABD-Q170P, EMD-7832; F20-F-actin-FLNaABD-E254K, EMD-8918; Krios-F-actin-FLNaABD-E254K, EMD-7831. The corresponding FLNaABD-E254K filament model was deposited in the PDB with accession number 6D8C. Source data for F-actin-targeting analyses (Figs. 2c,d,g,h, 3b ,c,e,f, 4d,e, 5c,d, and 6a,b) and co-sedimentation assays (Figs. 5g and 6d ) are available with the paper online. Other data are available from the corresponding author upon reasonable request.
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Statistical parameters
When statistical analyses are reported, confirm that the following items are present in the relevant location (e.g. figure legend, table legend, main text, or Methods section).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Our web collection on statistics for biologists may be useful.
Software and code
Policy information about availability of computer code
Data collection
Micro-Manager was used to facilitate fluorescence microcsopy image collection.
Data analysis
CellProfiler (2.1.1) was used to analyze fluorescence microscopy images. GraphPad Prism (Version 7) was used to generate data figures and perform statistical analyses (ANOVA and t-tests). For cryo-EM analysis: MotionCor2 was used to align and dose-correct cryo-EM micrographs; Gctf was used to calculate contrast transfer function parameters; RELION (version 2.0.3) was used for helical processing and structural refinement; UCSF Chimera were used to generate initial cryo-EM models; Phenix and Coot were used to refine EM models; MolProbilty was used to inspect cryo-EM models.
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
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Data Policy information about availability of data All manuscripts must include a data availability statement. This statement should provide the following information, where applicable: -Accession codes, unique identifiers, or web links for publicly available datasets -A list of figures that have associated raw data -A description of any restrictions on data availability Cryo-EM reconstructions were deposited in the Electron Microscopy Data Bank with the following accession numbers: F20-F-actin-FLNaABD 7833, F20-F-actin-FLNaABD-Q170P 7832, F20-F-actin-FLNaABD-E254K 8918, and Krios-F-actin-FLNaABD-E254K 7831. The corresponding FLNaABD-E254K filament model was deposited in the Protein Data Bank with accession number 6D8C. Source data for F-actin targeting analyses (Figs. 2c,d ,g,h, 3b,c,e,f, 4d,e, 5c,d, and 6a,b) and cosedimentation assays (Figs. 5g and 6d ) are available with the paper online. Other data are available from the corresponding author upon reasonable request.
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Sample size
Sample sizes are indicated in figure legends, and are based on previous experience with the assays and on established literature sample sizes to enable statistical analyses.
Data exclusions For F-actin targeting studies, images of cells were excluded from automated PCC scoring if they included more than one cell per field.
Replication
All replication attempts were successful.
Randomization Randomization was not applicable in these cell biology studies.
Blinding
For F-actin targeting studies, investigators were blind to which sample was being observed during fluorescence microscopy imaging and when being scored for F-actin targeting.
Reporting for specific materials, systems and methods Validation GFP antibody was validated by immunoblotting cell lysates transiently expressing GFP or GFP-tagged FLNaABD constructs; no bands were detected in non-transfected cells. Vinculin antibody was validated by immunoblot detection of a single band at the expected molecular weight as described by the commercial validation statement.
